Growing demand for ESD is driven by rising GI cancer rates, technological advancements, an aging population, and increased ...

Surging Prevalence of Gastrointestinal Cancers and Advancements in Therapeutic Endoscopy Fuel a Steady 5.51% CAGR in the Global ESD Landscape.Austin, United States, April 07, 2026 (GLOBE NEWSWIRE) -- ...

Gastric lesions include benign, dysplastic, and malignant tumours. Patients may be asymptomatic or experience loss of appetite and weight, anaemia and abdominal discomfort or pain. The procedure is ...

Colorectal lesions may be benign, premalignant or malignant. Patients may be asymptomatic or may present with blood in the stool, change in bowel habit, abdominal pain or unexplained weight loss. In ...

Early detection of colon cancer is key to survival. New guidance advises endoscopists in identifying malignant colorectal polyps and recommendations for surgery. New guidance released by the US ...

Doctors are using endoscopic submucosal dissection (ESD) to remove some early gastrointestinal tumors without making external cuts, a shift that can speed recovery and keep organs intact when cancers ...

Endoscopic submucosal dissection (ESD) of large colorectal adenomas resulted in a lower recurrence rate compared with endoscopic mucosal resection (EMR), but the more technically complex ESD had a ...

Endoscopic submucosal dissection to remove large colorectal lesions was performed safely and successfully in an outpatient setting, based on data from more than 600 patients. The widespread adoption ...

OAK BROOK, Ill. – January 27, 2009 – A prospective clinical trial from researchers in Japan shows magnetic-anchor-guided endoscopic submucosal dissection for large early gastric cancer to be a ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--EndoClot Plus, Inc. (EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot ® Submucosal Injection Agent (EndoClot ® SIA) ...